Douglas signs new cancer drug R&D deal with Manchester Uni

Douglas signs new cancer drug R&D deal with Manchester Uni
Paul McBeth
By Paul McBeth Feb. 1 (BusinessDesk) - Douglas Pharmaceuticals, the country's biggest drugs developer and manufacturer, has signed a research and licensing deal with the University of Manchester's innovation unit, UMI3, to repurpose an HIV drug to prevent early-stage cervical cancer.  Auckland-based Douglas Pharmaceuticals will sponsor research at Manchester University to build on work, including a phase one trial in Kenya, that's found a drug commonly used to treat HIV was active against human papilloma virus (HPV), which causes almost a...